Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05055323 · ClinicalTrials.gov registry record · Phase 1

A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer

A Phase 1 study of Stage II Pancreatic Cancer AJCC v8 and Stage IIA Pancreatic Cancer AJCC v8, sponsored by Thomas Jefferson University.

Active
Registry status
Phase 1
Development phase
20
Enrollment target
1
Study location

NCT05055323 is a Phase 1 study of Stage II Pancreatic Cancer AJCC v8 and Stage IIA Pancreatic Cancer AJCC v8 that is active but no longer recruiting, run by Thomas Jefferson University. The registered enrollment target is 20 participants, below the 63-participant average among 16 other Stage II Pancreatic Cancer AJCC v8 trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05055323, a Phase 1 study of Stage II Pancreatic Cancer AJCC v8 and Stage IIA Pancreatic Cancer AJCC v8, is active but no longer recruiting, sponsored by Thomas Jefferson University.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

This phase I trial studies the side effects and best dose of pyrvinium pamoate for the treatment of pancreatic ductal adenocarcinoma that cannot be removed by surgery (resectable). Pyrvinium pamoate may slow down tumor growth and help patients live longer.

Conditions Studied

Stage II Pancreatic Cancer AJCC v8 Stage IIA Pancreatic Cancer AJCC v8 Resectable Pancreatic Ductal Adenocarcinoma Stage IIB Pancreatic Cancer AJCC v8 Stage I Pancreatic Cancer AJCC v8 Stage 0 Pancreatic Cancer AJCC v8 Stage IA Pancreatic Cancer AJCC v8 Stage IB Pancreatic Cancer AJCC v8

Interventions

  • DRUG Pyrvinium Pamoate

Study Locations (1)

Pennsylvania

  • Thomas Jefferson University - Philadelphia

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2021-07-29
Est. Completion 2026-12-31
Phase Phase 1

Sponsor

Thomas Jefferson University

292 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05055323

The ClinicalTrials.gov registry entry for NCT05055323 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 63-participant average among 16 other Stage II Pancreatic Cancer AJCC v8 trials with a reported enrollment target (68% lower). The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.

The record links to 8 conditions, with Stage II Pancreatic Cancer AJCC v8 appearing as the primary indexed condition, and to 1 intervention - of which Pyrvinium Pamoate is the first listed.

NCT05055323 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT05055323 about?

NCT05055323 is a clinical study titled "A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer". This phase I trial studies the side effects and best dose of pyrvinium pamoate for the treatment of pancreatic ductal adenocarcinoma that cannot be removed by surgery (resectable). Pyrvinium pamoate may slow down tumor growth and help patients live longer.

What is the current status of trial NCT05055323?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2021-07-29. Estimated completion is 2026-12-31.

What conditions does trial NCT05055323 study?

This clinical trial studies the following conditions: Stage II Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8, Resectable Pancreatic Ductal Adenocarcinoma, Stage IIB Pancreatic Cancer AJCC v8, Stage I Pancreatic Cancer AJCC v8.

What interventions are being tested in trial NCT05055323?

The interventions under investigation include: Pyrvinium Pamoate (DRUG).

Who is sponsoring clinical trial NCT05055323?

This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05055323 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Stage II Pancreatic Cancer AJCC v8

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Stage II Pancreatic Cancer AJCC v8

All registered trials for this condition

Stage IIA Pancreatic Cancer AJCC v8

All registered trials for this condition

Pennsylvania

All trials with a study site in Pennsylvania

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.